% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • insm_info_repost insm_info_repost Apr 5, 2014 11:50 AM Flag

    Poster at ATS Tuesday 20 May

    By the way, details of the Poster session are already on the ATS website:

    Poster Discussion Session: Tuesday, May 20, 8:15 AM - 10:45AM,
    Sapphire Ballroom E-F (Level 4), Hilton San Diego Bayfront
    Poster Viewing: 8:15-9:15, Discussion: 9:15-10:45
    A Randomized, Double-Blind, Placebo-Controlled Study Of Liposomal Amikacin For Inhalation (Arikace®) In Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease


    The abstract has a few more interesting details:
    90 randomized 19% CF, 81% non CF
    64% MAC, 36% M-Abs
    90 started, 1 died
    89 completed
    72 continued into open label
    41 of which have already finished

    the deadline for poster submission is March 30th (because they are peer reviewed); therefore insmed knows a lot more detail than was discussed yesterday.

    insmed is an exhibitor too (booth #2933)

    By the way, the abstract refers to 590mg dosage (as did yesterday's PR). Curious: it has always been 560mg until now. typo? hmmm...

    Also (keep in mind) by mid-May the FDA MUST respond (with 60 calendar days) to Insmed's request regarding Breakthrough Therapy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • OK, can anyone explain exactly what will go on here? The way I read it, the poster viewing will last one hour....and then there will be a discussion for 1 1/2 hours? Is this normal? Anyone going?


      • 1 Reply to insmhistorian
      • michael_coen Apr 5, 2014 5:53 PM Flag

        The poster will contain more details/data from the trial.
        At least one knowledgeable expert will be on hand stood next to the poster to answer questions (for about 90 mins - the poster stays up all day).

        In addition, Felix Ratjen is chairing a separate technical session (I think on Weds) which is also related.
        It's all on the ATS site.

        I would like to go, but probably can't (other commitments).
        I expect FDA to say "yes" to Breakthrough Therapy by then anyway and I expect Insmed to publish the poster on their website (perhaps the day after).

16.99+0.40(+2.41%)Nov 27 1:00 PMEST